| Symbol | SCNX |
|---|---|
| Name | SCIENTURE HOLDINGS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Other Pharmaceuticals |
| Address | 3840 LAND O LAKES BOULEVARD,LAND O LAKES, PASCO, Florida, 34639, United States |
| Telephone | +1 800 261-0281 |
| Fax | — |
| — | |
| Website | vhttps://www.scienture.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001382574 |
| Description | Scienture Holdings, Inc., formerly TRxADE Health, Inc., is a comprehensive health services and pharmaceutical product company focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs, optimize the prescription journey and patient engagement in the United States. It operates through Scienture, LLC and Integra Pharma Solutions, LLC. Scienture, LLC is a branded specialty pharmaceutical company. Its assets in development are across therapeutics areas, indications and cater to different market segments. Its products include SCN - 102 (Cardiovascular), SCN - 104 (CNS-Pain), SCN - 105 (CNS), SCN - 106 (Cardiovascular) and SCN - 107 (Pain). Integra Pharma Solutions, LLC is the pharmaceutical supplier of choice for healthcare organizations of all sizes. Its expertise in the distribution of products extends to all healthcare markets including government organizations, hospitals, clinics, and independent pharmacies nationwide. Additional info from NASDAQ: |
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
Read moreSCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
Read moreSCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
Read more(99% Neutral) SCIENTURE HOLDINGS, INC. (SCNX) Announces New Board Appointment
Read more(30% Negative) SCIENTURE HOLDINGS, INC. (SCNX) Reports Q2 2026 Financial Results
Read moreSCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
Read moreScienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
Read moreSCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
Read more(30% Negative) SCIENTURE HOLDINGS, INC. (SCNX) Announces Business Combination
Read moreNew Form 10-K/A - Scienture Holdings, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001493152-26-020707 <b>Size:</b> 937 KB
Read more